Clinical trials: Infliximab
Rheumatoid Arthritis
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against rheumatoid arthritis under actual status of use.
- Trial name
- NCT03885037
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 77 people
- Sponsor
- Pfizer
Immune-related Colitis
EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis
The photoactivating agent UVADEX (methoxsalen) is used in conjunction with extracorporeal photopheresis (ECP) as an immunomodulatory therapy approved for the treatment of cutaneous T-cell lymphoma.
- Trial name
- EPIC (NCT06646016)
- Testing
- Methoxsalen, Infliximab, Vedolizumab
- Where
- United States
- Sponsor
- Therakos LLC
Acute Severe Ulcerative Colitis
Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result…
- Trial name
- NCT07297069
- Testing
- Infliximab, Tofacitinib
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn Disease (CD)
A Study on the Relationship of Interleukin-7 Receptor Gene Polymorphisms With the Risk of Crohn's Disease Onset and the Efficacy of Infliximab
From January 2020 to May 2025, 303 CD patients and 514 normal controls were retrospectively collected from Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University.
- Trial name
- NCT07263477
- Testing
- Infliximab
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Multisystem Inflammatory Syndrome-Children
MIS-C Comparative Effectiveness Study
In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus.
- Trial name
- MISTIC (NCT04898231)
- Testing
- Infliximab, Anakinra, Methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of California, San Diego
IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis
A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority…
- Trial name
- NCT07120152
- Testing
- Subcutaneous infliximab CT-P13 Remsima®SC
- Volunteers
- 439 people, healthy volunteers welcome
- Sponsor
- Erwin Dreesen
Inflammatory Bowel Disease (Crohn&Amp;#39;s Disease and Ulcerative Colitis), Fecal Microbiota Transplantation
Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled Study
This study enrolled 94 patients with UC or CD. Two groups received either 8-week intestinal bacterial transplant capsule therapy or biological therapy, respectively.
- Trial name
- NCT07149441
- Testing
- Fecal microbiota transplantation, infliximab
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Shanghai 10th People's Hospital
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Depression
A Study of Infliximab for Treatment Resistant Major Depression
Major depression is increasingly recognized to be a chronic and highly recurrent condition, which results in significantly increased health problems.
- Trial name
- Infliximab (NCT00463580)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Ulcerative Colitis
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that results from immune dysregulation. Arguably, the development of Tumor Necrosis Factor (TNF) antagonists (including infliximab, adalimumab and golimumab)…
- Trial name
- EFFICACI (NCT03679546)
- Testing
- Infliximab, Vedolizumab Injection
- Where
- 19 sites in France
- Volunteers
- 151 people
- Sponsor
- Rennes University Hospital
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Colitis,Ulcerative
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of…
- Trial name
- BIOSTOP (NCT03011268)
- Testing
- Discontinuation of anti-TNF treatment, Continuation of anti-TNF treatment
- Where
- 19 sites in Norway
- Volunteers
- 174 people
- Sponsor
- Helse Møre og Romsdal HF
Crohn Disease
Post-Operative Crohn's Disease Outcome in Children
Objectives: To examine the effect of prophylaxis therapy on clinical and endoscopic disease recurrence in children with Crohn's Disease (CD) following ileo-cecal resection.
- Trial name
- POPCORN (NCT03681652)
- Testing
- Azathioprine, Anti-TNF Drug
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Schneider Children's Medical Center, Israel
Ulcerative Colitis, Inflammatory Bowel Diseases
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis.
- Trial name
- COMBO-UC (NCT06453317)
- Testing
- Infliximab, Ustekinumab
- Where
- Poland
- Volunteers
- 172 people
- Sponsor
- Medical University of Lodz
Crohn Disease
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the…
- Trial name
- NCT04312659
- Testing
- Infliximab
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Crohn's Disease, Ulcerative Colitis
Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against Crohn's disease or ulcerative colitis under actual status of use.
- Trial name
- NCT03884439
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 428 people
- Sponsor
- Pfizer
Inflammatory Bowel Diseases, Crohn Disease
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease
Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNFα (infliximab, adalimumab or golimumab), vedolizumab, ustekinumab and tofacitinib will be made…
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
- Trial name
- BioIBD (NCT03885713)
- Testing
- Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
- Where
- 21 sites in Spain
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROMPT-IBD (NCT06758024)
- Testing
- Infliximab
- Where
- Chile
- Volunteers
- 72 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Colitis, Ulcerative
TITRATE (inducTIon for acuTe ulceRATivE Colitis)
The aim of this study is to investigate whether intensive, personalized IFX dosing by using a pharmacokinetics driven dashboard system during the induction phase in patients with acute severe UC leads to increased treatment…
- Trial name
- TITRATE (NCT03937609)
- Testing
- Infliximab
- Where
- 7 sites in Ireland, Netherlands and 1 more
- Volunteers
- 50 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)